imaging biomarkers

Just imagine…you are planning a multi-center imaging study and you can choose whichever site you want irrespective of the MR scanner they have. In SIMAB, Fraunhofer MEVIS and mediri GmbH are developing a vendor-agnostic MR sequence development framework to increase the comparability of imaging biomarkers regardless of the employed scanner equipment.
Structural imaging biomarkers as brain atrophy or lesions will be assessed as well as functional indicators of neurological diseases, e.g. brain perfusion or permeability.
SIMAB is funded by the German Ministry for Research and Education.

World Multiple Sclerosis Day, as a day of global solidarity, emphasizes the need to raise awareness of this disease, improve diagnosis and treatment, and fund research to curb multiple sclerosis.

At mediri we develop and refine structural analysis methods to support the diagnosis and follow-up of multiple sclerosis.
An important imaging biomarker for MS is smouldering lesions. Their AI-aided detection on MR images also makes disease activity visible that cannot be seen with the naked eye.

We see a rapidly increasing need for medical imaging in clinical trials and in the development of standardized imaging biomarkers. In 2022, more than 1900 clinical trials were registered in Germany. In many of them, medical imaging is used in as a primary, quantitative and surrogate biomarker.

New AI developments across the healthcare industry, with radiology at the forefront, continue to increase the need for medical imaging core lab services.
As an Imaging CRO and Core Lab, we make your image-based clinical trials more efficient, faster and safer. This is especially important when it comes to multi-center studies that place high demands on comparability of image data.

Contact us to discuss our medical imaging solutions for reliable clinical trial results.

Working visit at Amsterdam UMC: The partners in the ASPIRE project spent two days at Amsterdam UMC to pave the way for the final year. ASPIRE will ease the access to non-invasiv imaging biomarkers in dementia and help to get ASL into the clinics.